Blueprint Medicines News

Analysts' Opinions Are Mixed on These Healthcare Stocks: Blueprint Medicines (BPMC), Adaptimmune Therapeutics (ADAP) and Ardelyx (ARDX)

TipRanksAug 7 02:06 ET

Blueprint Medicines Analyst Ratings

BenzingaAug 5 15:13 ET

Needham Maintains Buy on Blueprint Medicines, Raises Price Target to $133

BenzingaAug 5 15:13 ET

TD Cowen Maintains Blueprint Medicines(BPMC.US) With Buy Rating

Moomoo NewsAug 5 07:33 ET

Barclays Maintains Blueprint Medicines(BPMC.US) With Hold Rating, Raises Target Price to $105

Moomoo NewsAug 5 04:32 ET

Blueprint Medicines (BPMC) Receives a Hold From Barclays

TipRanksAug 5 03:56 ET

Blueprint Medicines Price Target Raised to $138.00/Share From $130.00 by Guggenheim

Dow JonesAug 2 15:20 ET

Blueprint Medicines Analyst Ratings

BenzingaAug 2 11:29 ET

A Quick Look at Today's Ratings for Blueprint Medicines(BPMC.US), With a Forecast Between $120 to $135

Moomoo NewsAug 2 09:02 ET

Blueprint Medicines Analyst Ratings

BenzingaAug 1 08:52 ET

Needham Maintains Blueprint Medicines(BPMC.US) With Buy Rating, Maintains Target Price $130

Moomoo NewsAug 1 08:40 ET

Buy Rating Affirmed: Blueprint Medicines Surpasses Q2 Revenue Estimates With Ayvakit's Success

TipRanksAug 1 08:10 ET

Blueprint Medicines Analyst Ratings

BenzingaJul 29 11:46 ET

Barclays Keeps Their Hold Rating on Blueprint Medicines (BPMC)

TipRanksJul 29 04:17 ET

Piper Sandler Keeps Their Hold Rating on Blueprint Medicines (BPMC)

TipRanksJul 23 06:45 ET

Stifel Nicolaus Remains a Buy on Blueprint Medicines (BPMC)

TipRanksJul 19 08:18 ET

Blueprint Medicines Analyst Ratings

BenzingaJul 12 13:18 ET

Morgan Stanley Maintains Equal-Weight on Blueprint Medicines, Raises Price Target to $115

BenzingaJul 12 13:18 ET

Blueprint Medicines (BPMC) Receives a Hold From Morgan Stanley

TipRanksJul 12 08:41 ET

Oppenheimer Adjusts Price Target on Blueprint Medicines to $125 From $114, Maintains Outperform Rating

MT NewswiresJul 8 09:27 ET